News Formal

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition

  • 📰 Forbes
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 53%

Belgique Nouvelles Nouvelles

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
Belgique Dernières Nouvelles,Belgique Actualités

Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.

Biogen will pay $172.50 per share in cash for Reata, which had a Thursday closing price of $108.

55), andThe company was founded in Plano, Texas in 2002 and focuses on antioxidative and anti-inflammatory drugsBiogen, a Massachusetts-based biotech company with a market cap of nearly $38 billion, has acquired three other companies in the last eight years. The $200 million

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Forbes /  🏆 394. in BE
 

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion AcquisitionBiogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion AcquisitionBiogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.
La source: Forbes - 🏆 394. / 53 Lire la suite »

Biogen to bulk up rare disease treatments with $7 billion Reata acquisitionBiogen to bulk up rare disease treatments with $7 billion Reata acquisitionBiogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.
La source: WashTimes - 🏆 235. / 63 Lire la suite »